IB 
Union Calendar No. 33 
116TH CONGRESS 
1ST SESSION 
H. R. 965 
[Report No. 116–55, Parts I and II] 
To promote competition in the market for drugs and biological products 
by facilitating the timely entry of lower-cost generic and biosimilar 
versions of those drugs and biological products. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 5, 2019 
Mr. CICILLINE (for himself, Mr. SENSENBRENNER, Mr. NADLER, Mr. COL-
LINS of Georgia, Mr. WELCH, and Mr. MCKINLEY) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committee on the Judiciary, for a period 
to be subsequently determined by the Speaker, in each case for consider-
ation of such provisions as fall within the jurisdiction of the committee 
concerned 
MAY 10, 2019 
Additional sponsors: Mr. MEADOWS, Ms. FINKENAUER, Mr. DOGGETT, Mr. 
COLE, Mr. GALLAGHER, Mr. LIPINSKI, Mr. RUSH, Ms. MCCOLLUM, Mr. 
PALLONE, Mr. PERRY, Mr. RUIZ, Mrs. DINGELL, Ms. ESHOO, Ms. MAT-
SUI, Mrs. CRAIG, Mr. TONKO, Mr. GOHMERT, Mr. VAN DREW, Ms. 
CLARKE of New York, Mr. COURTNEY, Mr. ALLRED, Ms. SCHAKOWSKY, 
Mr. CROW, Mr. GONZALEZ of Ohio, Mr. LARSON of Connecticut, Mr. 
MCADAMS, Mr. SCHRADER, Mr. RODNEY DAVIS of Illinois, Mr. PAPPAS, 
Mr. 
KENNEDY, 
Ms. 
DAVIDS
of 
Kansas, 
Mr. 
NORCROSS, 
Ms. 
SPANBERGER, Mr. QUIGLEY, Mr. DEUTCH, Mr. LANGEVIN, Mr. COOPER, 
Mrs. MCBATH, Mr. RASKIN, Ms. MUCARSEL-POWELL, Mr. STANTON, Mr. 
JORDAN, Ms. WILD, Mr. COHEN, Mr. KIM, Ms. SCHRIER, Mr. JOYCE of 
Ohio, Mr. CASE, Mr. KHANNA, Mr. DAVID SCOTT of Georgia, Ms. 
HOULAHAN, Mr. CASTEN of Illinois, Mr. NORMAN, Ms. PINGREE, Mr. 
CARBAJAL, Mr. SMITH of Washington, Ms. WEXTON, Mr. CISNEROS, Mr. 
CONNOLLY, Ms. UNDERWOOD, Ms. GARCIA of Texas, Ms. MENG, and 
Mrs. BUSTOS 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
MAY 10, 2019 
Reported from the Committee on Energy and Commerce with an amendment 
[Strike out all after the enacting clause and insert the part printed in italic] 
MAY 10, 2019 
Reported from the Committee on the Judiciary; committed to the Committee 
of the Whole House on the State of the Union and ordered to be printed 
[For text of introduced bill, see copy of bill as introduced on February 5, 2019] 
A BILL 
To promote competition in the market for drugs and biologi-
cal products by facilitating the timely entry of lower- 
cost generic and biosimilar versions of those drugs and 
biological products. 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6652
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Creating and Restoring 
Equal Access to Equivalent Samples Act of 2019’’ or the 
‘‘CREATES Act of 2019’’. 
SEC. 2. ACTIONS FOR DELAYS OF GENERIC DRUGS AND BIO-
SIMILAR BIOLOGICAL PRODUCTS. 
(a) DEFINITIONS.—In this section— 
(1) the term ‘‘commercially reasonable, market- 
based terms’’ means— 
(A) a nondiscriminatory price for the sale 
of the covered product at or below, but not great-
er than, the most recent wholesale acquisition 
cost for the drug, as defined in section 
1847A(c)(6)(B) of the Social Security Act (42 
U.S.C. 1395w–3a(c)(6)(B)); 
(B) a schedule for delivery that results in 
the transfer of the covered product to the eligible 
product developer consistent with the timing 
under subsection (b)(2)(A)(iv); and 
(C) no additional conditions are imposed 
on the sale of the covered product; 
(2) the term ‘‘covered product’’— 
(A) means— 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
(i) any drug approved under sub-
section (c) or (j) of section 505 of the Fed-
eral Food, Drug, and Cosmetic Act (21 
U.S.C. 355) or biological product licensed 
under subsection (a) or (k) of section 351 of 
the Public Health Service Act (42 U.S.C. 
262); 
(ii) any combination of a drug or bio-
logical product described in clause (i); or 
(iii) when reasonably necessary to sup-
port approval of an application under sec-
tion 505 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355), or section 
351 of the Public Health Service Act (42 
U.S.C. 262), as applicable, or otherwise 
meet the requirements for approval under 
either such section, any product, including 
any device, that is marketed or intended for 
use with such a drug or biological product; 
and 
(B) does not include any drug or biological 
product that appears on the drug shortage list in 
effect under section 506E of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 356e), un-
less— 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
(i) the drug or biological product has 
been on the drug shortage list in effect 
under such section 506E continuously for 
more than 6 months; or 
(ii) the Secretary determines that in-
clusion of the drug or biological product as 
a covered product is likely to contribute to 
alleviating or preventing a shortage. 
(3) the term ‘‘device’’ has the meaning given the 
term in section 201 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 321); 
(4) the term ‘‘eligible product developer’’ means 
a person that seeks to develop a product for approval 
pursuant to an application for approval under sub-
section (b)(2) or (j) of section 505 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355) or for 
licensing pursuant to an application under section 
351(k) of the Public Health Service Act (42 U.S.C. 
262(k)); 
(5) the term ‘‘license holder’’ means the holder of 
an application approved under subsection (c) or (j) of 
section 505 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 355) or the holder of a license under 
subsection (a) or (k) of section 351 of the Public 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
Health Service Act (42 U.S.C. 262) for a covered 
product; 
(6) the term ‘‘REMS’’ means a risk evaluation 
and mitigation strategy under section 505–1 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
355–1); 
(7) the term ‘‘REMS with ETASU’’ means a 
REMS that contains elements to assure safe use under 
section 505–1(f) of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 355–1(f)); 
(8) the term ‘‘Secretary’’ means the Secretary of 
Health and Human Services; 
(9) the term ‘‘single, shared system of elements to 
assure safe use’’ means a single, shared system of ele-
ments to assure safe use under section 505–1(f) of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
355–1(f)); and 
(10) the term ‘‘sufficient quantities’’ means an 
amount of a covered product that the eligible product 
developer determines allows it to— 
(A) conduct testing to support an applica-
tion under— 
(i) subsection (b)(2) or (j) of section 
505 of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 355); or 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
(ii) section 351(k) of the Public Health 
Service Act (42 U.S.C. 262(k)); and 
(B) fulfill any regulatory requirements re-
lating to approval of such an application. 
(b) CIVIL ACTION FOR FAILURE TO PROVIDE SUFFI-
CIENT QUANTITIES OF A COVERED PRODUCT.— 
(1) IN GENERAL.—An eligible product developer 
may bring a civil action against the license holder for 
a covered product seeking relief under this subsection 
in an appropriate district court of the United States 
alleging that the license holder has declined to provide 
sufficient quantities of the covered product to the eli-
gible product developer on commercially reasonable, 
market-based terms. 
(2) ELEMENTS.— 
(A) IN GENERAL.—To prevail in a civil ac-
tion brought under paragraph (1), an eligible 
product developer shall prove, by a preponder-
ance of the evidence— 
(i) that— 
(I) the covered product is not sub-
ject to a REMS with ETASU; or 
(II) if the covered product is sub-
ject to a REMS with ETASU— 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
by the date that is 31 days after the 
date on which the license holder re-
ceived the request for the covered prod-
uct; and 
(II) for a covered product that is 
subject to a REMS with ETASU, by 
31 days after the later of— 
(aa) the date on which the li-
cense holder received the request 
for the covered product; or 
(bb) the date on which the li-
cense holder received a copy of the 
covered 
product 
authorization 
issued by the Secretary in accord-
ance with subparagraph (B). 
(B) AUTHORIZATION FOR COVERED PROD-
UCT SUBJECT TO A REMS WITH ETASU.— 
(i) REQUEST.—An eligible product de-
veloper may submit to the Secretary a writ-
ten request for the eligible product developer 
to be authorized to obtain sufficient quan-
tities of an individual covered product sub-
ject to a REMS with ETASU. 
(ii) AUTHORIZATION.—Not later than 
120 days after the date on which a request 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
under clause (i) is received, the Secretary 
shall, by written notice, authorize the eligi-
ble product developer to obtain sufficient 
quantities of an individual covered product 
subject to a REMS with ETASU for pur-
poses of— 
(I) development and testing that 
does not involve human clinical trials, 
if the eligible product developer has 
agreed to comply with any conditions 
the Secretary determines necessary; or 
(II) development and testing that 
involves human clinical trials, if the 
eligible product developer has— 
(aa)(AA) submitted protocols, 
informed consent documents, and 
informational materials for test-
ing that include protections that 
provide safety protections com-
parable to those provided by the 
REMS for the covered product; or 
(BB) otherwise satisfied the 
Secretary that such protections 
will be provided; and 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
(bb) met any other require-
ments the Secretary may estab-
lish. 
(iii) NOTICE.—A covered product au-
thorization issued under this subparagraph 
shall state that the provision of the covered 
product by the license holder under the 
terms of the authorization will not be a vio-
lation of the REMS for the covered product. 
(3) AFFIRMATIVE DEFENSE.—In a civil action 
brought under paragraph (1), it shall be an affirma-
tive defense, on which the defendant has the burden 
of persuasion by a preponderance of the evidence— 
(A) that, on the date on which the eligible 
product developer requested to purchase sufficient 
quantities of the covered product from the license 
holder— 
(i) neither the license holder nor any of 
its agents, wholesalers, or distributors was 
engaged in the manufacturing or commer-
cial marketing of the covered product; and 
(ii) neither the license holder nor any 
of its agents, wholesalers, or distributors 
otherwise had access to inventory of the cov-
ered product to supply to the eligible prod-
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
uct developer on commercially reasonable, 
market-based terms; 
(B) that— 
(i) the license holder sells the covered 
product through agents, distributors, or 
wholesalers; 
(ii) the license holder has placed no re-
strictions, explicit or implicit, on its agents, 
distributors, or wholesalers to sell covered 
products to eligible product developers; and 
(iii) the covered product can be pur-
chased by the eligible product developer in 
sufficient quantities on commercially rea-
sonable, 
market-based 
terms 
from 
the 
agents, distributors, or wholesalers of the li-
cense holder; or 
(C) that the license holder made an offer to 
sell sufficient quantities of the covered product to 
the eligible product developer at commercially 
reasonable market-based terms— 
(i) for a covered product that is not 
subject to a REMS with ETASU, by the 
date that is 14 days after the date on which 
the license holder received the request for the 
covered product, and the eligible product de-
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
veloper did not accept such offer by the date 
that is 7 days after the date on which the 
eligible product developer received such offer 
from the license holder; or 
(ii) for a covered product that is sub-
ject to a REMS with ETASU, by the date 
that is 20 days after the date on which the 
license holder received the request for the 
covered product, and the eligible product de-
veloper did not accept such offer by the date 
that is 10 days after the date on which the 
eligible product developer received such offer 
from the license holder. 
(4) METHODS FOR TRANSMISSION OF REQUESTS 
FOR COVERED PRODUCTS.—A written request for a 
covered product, offer to sell a covered product, or ac-
ceptance of such an offer between the eligible product 
developer and the license holder shall be made by— 
(A) certified or registered mail with return 
receipt requested; 
(B) personal delivery; or 
(C) electronic means. 
(5) REMEDIES.— 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
(A) IN GENERAL.—If an eligible product de-
veloper prevails in a civil action brought under 
paragraph (1), the court shall— 
(i) order the license holder to provide 
to the eligible product developer without 
delay sufficient quantities of the covered 
product on commercially reasonable, mar-
ket-based terms; 
(ii) award to the eligible product devel-
oper reasonable attorney’s fees and costs of 
the civil action; and 
(iii) award to the eligible product de-
veloper a monetary amount sufficient to 
deter the license holder from failing to pro-
vide eligible product developers with suffi-
cient quantities of a covered product on 
commercially 
reasonable, 
market-based 
terms, if the court finds, by a preponder-
ance of the evidence— 
(I) that the license holder delayed 
providing sufficient quantities of the 
covered product to the eligible product 
developer without a legitimate business 
justification; or 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
(II) that the license holder failed 
to comply with an order issued under 
clause (i). 
(B) 
MAXIMUM
MONETARY
AMOUNT.—A 
monetary amount awarded under subparagraph 
(A)(iii) shall not be greater than the revenue that 
the license holder earned on the covered product 
during the period— 
(i) beginning on— 
(I) for a covered product that is 
not subject to a REMS with ETASU, 
the date that is 31 days after the date 
on which the license holder received the 
request; or 
(II) for a covered product that is 
subject to a REMS with ETASU, the 
date that is 31 days after the later of— 
(aa) the date on which the li-
cense holder received the request; 
or 
(bb) the date on which the li-
cense holder received a copy of the 
covered 
product 
authorization 
issued by the Secretary in accord-
ance with paragraph (2)(B); and 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
(ii) ending on the date on which the el-
igible product developer received sufficient 
quantities of the covered product. 
(C) AVOIDANCE OF DELAY.—The court may 
issue an order under subparagraph (A)(i) before 
conducting further proceedings that may be nec-
essary to determine whether the eligible product 
developer is entitled to an award under clause 
(ii) or (iii) of subparagraph (A), or the amount 
of any such award. 
(c) LIMITATION OF LIABILITY.—A license holder for a 
covered product shall not be liable for any claim under Fed-
eral, State, or local law arising out of the failure of an 
eligible product developer to follow adequate safeguards to 
assure safe use of the covered product during development 
or testing activities described in this section, including 
transportation, handling, use, or disposal of the covered 
product by the eligible product developer. 
(d) NO VIOLATION OF REMS.—Section 505–1 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) 
is amended by adding at the end the following new sub-
section: 
‘‘(l) PROVISION OF SAMPLES NOT A VIOLATION OF 
STRATEGY.—The provision of samples of a covered product 
to an eligible product developer (as those terms are defined 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
in section 2(a) of the Creating and Restoring Equal Access 
to Equivalent Samples Act of 2019) shall not be considered 
a violation of the requirements of any risk evaluation and 
mitigation strategy that may be in place under this section 
for such drug.’’. 
(e) RULE OF CONSTRUCTION.— 
(1) DEFINITION.—In this subsection, the term 
‘‘antitrust laws’’— 
(A) has the meaning given the term in sub-
section (a) of the first section of the Clayton Act 
(15 U.S.C. 12); and 
(B) includes section 5 of the Federal Trade 
Commission Act (15 U.S.C. 45) to the extent that 
such section applies to unfair methods of com-
petition. 
(2) ANTITRUST LAWS.—Nothing in this section 
shall be construed to limit the operation of any provi-
sion of the antitrust laws. 
SEC. 3. REMS APPROVAL PROCESS FOR SUBSEQUENT FIL-
ERS. 
Section 505–1 of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 355–1), as amended by section 2, is 
further amended— 
(1) in subsection (g)(4)(B)— 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
(A) in clause (i) by striking ‘‘or’’ after the 
semicolon; 
(B) in clause (ii) by striking the period at 
the end and inserting ‘‘; or’’; and 
(C) by adding at the end the following: 
‘‘(iii) accommodate different, com-
parable aspects of the elements to assure 
safe use for a drug that is the subject of an 
application under section 505(j), and the 
applicable listed drug.’’; 
(2) in subsection (i)(1), by striking subpara-
graph (C) and inserting the following: 
‘‘(C)(i) Elements to assure safe use, if re-
quired under subsection (f) for the listed drug, 
which, subject to clause (ii), for a drug that is 
the subject of an application under section 505(j) 
may use— 
‘‘(I) a single, shared system with the 
listed drug under subsection (f); or 
‘‘(II) a different, comparable aspect of 
the elements to assure safe use under sub-
section (f). 
‘‘(ii) The Secretary may require a drug that 
is the subject of an application under section 
505(j) and the listed drug to use a single, shared 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
system under subsection (f), if the Secretary de-
termines that no different, comparable aspect of 
the elements to assure safe use could satisfy the 
requirements of subsection (f).’’; 
(3) in subsection (i), by adding at the end the 
following: 
‘‘(3) SHARED REMS.—If the Secretary approves, 
in accordance with paragraph (1)(C)(i)(II), a dif-
ferent, comparable aspect of the elements to assure 
safe use under subsection (f) for a drug that is the 
subject of an abbreviated new drug application under 
section 505(j), the Secretary may require that such 
different comparable aspect of the elements to assure 
safe use can be used with respect to any other drug 
that is the subject of an application under section 
505(j) or 505(b) that references the same listed drug.’’; 
and 
(4) by adding at the end the following: 
‘‘(m) SEPARATE REMS.—When used in this section, 
the terms ‘different, comparable aspect of the elements to 
assure safe use’ or ‘different, comparable approved risk eval-
uation and mitigation strategies’ means a risk evaluation 
and mitigation strategy for a drug that is the subject of 
an application under section 505(j) that uses different 
methods or operational means than the strategy required 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
under subsection (a) for the applicable listed drug, or other 
application under section 505(j) with the same such listed 
drug, but achieves the same level of safety as such strategy.’’. 
SEC. 4. RULE OF CONSTRUCTION. 
(a) IN GENERAL.—Nothing in this Act, the amend-
ments made by this Act, or in section 505–1 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355–1), shall be 
construed as— 
(1) prohibiting a license holder from providing 
an eligible product developer access to a covered prod-
uct in the absence of an authorization under this Act; 
or 
(2) in any way negating the applicability of a 
REMS with ETASU, as otherwise required under 
such section 505–1, with respect to such covered prod-
uct. 
(b) DEFINITIONS.—In this section, the terms ‘‘covered 
product’’, ‘‘eligible product developer’’, ‘‘license holder’’, and 
‘‘REMS with ETASU’’ have the meanings given such terms 
in section 3(a). 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6203
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS
Union Calendar No. 33 
116TH CONGRESS 
1ST SESSION 
H. R. 965 
[Report No. 116–55, Parts I and II] 
A BILL 
To promote competition in the market for drugs 
and biological products by facilitating the timely 
entry of lower-cost generic and biosimilar 
versions of those drugs and biological products. 
MAY 10, 2019 
Reported from the Committee on Energy and Commerce 
with an amendment 
MAY 10, 2019 
Reported from the Committee on the Judiciary; com-
mitted to the Committee of the Whole House on the 
State of the Union and ordered to be printed 
VerDate Sep 11 2014 
01:50 May 11, 2019
Jkt 089200
PO 00000
Frm 00022
Fmt 6651
Sfmt 6651
E:\BILLS\H965.RH
H965
pamtmann on DSKBFK8HB2PROD with BILLS